Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 17/20 | 0.74 |
| ▸ | EDNRB | P24530 | 8/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | DHPS | P49366 | 1/20 | 0.68 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.68 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7565870 | 0.90 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7948207 | 0.87 | EDNRA (0.70) | EDNRAEDNRB | |
| SCHEMBL7296746 | 0.85 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7569416 | 0.84 | EDNRA (0.59) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL2441280 | 0.83 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL8326901 | 0.83 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7296618 | 0.83 | EDNRA (0.80) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7949160 | 0.83 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7582530 | 0.83 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7295188 | 0.82 | EDNRA (0.82) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | claimed |
| JP-2930731-B2 | — | — | 1999-08-03 | — | — | JP | claimed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| EP-0799206-B1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6133442-A | FOR THE TREATMENT OF DISORDERS WHICH ARE ASSOCIATED WITH ENDOTHELIN ACTIVITIES, ESPECIALLY CIRCULATORY DISORDERS SUCH AS HYPERTENSION, ISCHAEMIA, VASOSPASMS AND ANGINA PECTORIS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0799206-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019455-A1 | ARYL- AND HETARYL-SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |